Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.

Cost of Revenue Trends: GSK vs. BioMarin (2014-2023)

__timestampBioMarin Pharmaceutical Inc.GSK plc
Wednesday, January 1, 20141297640007323000000
Thursday, January 1, 20151520080008853000000
Friday, January 1, 20162096200009290000000
Sunday, January 1, 201724178600010342000000
Monday, January 1, 201831526400010241000000
Tuesday, January 1, 201935946600011863000000
Wednesday, January 1, 202052427200011704000000
Friday, January 1, 202147051500011603000000
Saturday, January 1, 20224836690009554000000
Sunday, January 1, 20235770650008565000000
Monday, January 1, 2024580235000
Loading chart...

Unleashing the power of data

Analyzing Cost of Revenue: GSK plc vs. BioMarin Pharmaceutical Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for GSK plc and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, GSK plc consistently reported a higher cost of revenue, peaking in 2019 with a 62% increase from 2014. In contrast, BioMarin Pharmaceutical Inc. showed a more dynamic growth, with a staggering 345% rise in cost of revenue by 2023. This trend reflects BioMarin's aggressive expansion and investment in research and development. Meanwhile, GSK's cost fluctuations suggest strategic shifts in its operational focus. As the pharmaceutical landscape continues to change, these insights provide a window into the financial strategies of two industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025